Efeitos pleiotrópicos das estatinas na sepse
Conteúdo do artigo principal
Resumo
O objetivo do presente estudo foi revisar os efeitos da terapia com estatinas em pacientes com quadro de sepse. Foi realizada uma busca bibliográfica de artigos na base de dados MEDLINE/PubMed, SciELO e LILACS, no período de publicação delimitado entre 2009 e 2013. Foram incluídos artigos referentes a ensaios clínicos randomizados controlados e estudos de coorte observacionais clínicos. Foram encontrados diversos estudos clínicos e observacionais que investigaram o efeito do uso de estatinas em infecções e em sepse, tanto de uso contínuo pré-hospitalar (com ou sem interrupção durante internação) ou com início imediato pós-internação. Alguns estudos descrevem prováveis efeitos positivos e benéficos da terapia com estatinas no quadro de sepse, dentre eles a melhora dos parâmetros inflamatórios e da taxa de mortalidade, porém, esses resultados não se sustentam quando são aplicados métodos estatísticos que levam em conta diferentes variáveis, tais como idade, sexo, comorbidades e gravidade da doença. Até o momento nenhum estudo demonstrou evidências sólidas e significativas quanto à redução de mortalidade e morbidade no quadro séptico associado ao uso de estatinas, indicando que seu efeito benéfico e protetor ainda não foi plenamente delimitado, sendo necessários mais estudos que confirmem os resultados até agora encontrados.
Downloads
Detalhes do artigo
Autores que publicam nesta revista concordam com os seguintes termos:
- Autores mantém os direitos autorais e concedem à revista o direito de primeira publicação, com o trabalho simultaneamente licenciado sob uma licença Creative Commons CC BY que permite o compartilhamento e adaptação do trabalho com reconhecimento da autoria e publicação inicial nesta revista.
- Autores têm autorização para assumir contratos adicionais separadamente, para distribuição não-exclusiva da versão do trabalho publicada nesta revista (ex.: publicar em repositório institucional ou como capítulo de livro), com reconhecimento de autoria e publicação inicial nesta revista.
Referências
Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003;348(16):1546-54. http://dx.doi.org/10.1056/NEJMoa022139
Hospital Sírio Libanês [Internet]. Diagnóstico e tratamento precoces da sepse em adulto: protocolo institucional. Disponível em: http://www.hospitalsiriolibanes.org.br/sociedade-beneficente-senhoras/Documents/protocolos-institucionais/protocolo-sepse.pdf. Acesso em: 27 jun. 2013.
Usinger J, Kazama H, McDonough JS, Griffith TS, Hotchkiss RS, Ferguson TA. Sepsis-induced apoptosis leads to active suppression of delayed-type hypersensitivity by CD8+ regulatory T cells trough a TRAIL-dependent mechanism. J Immunol. 2010;184(12):6766-72. http://dx.doi.org/10.4049/jimmunol.0904054
Remick DG. Pathophysiology of sepsis. Am J Pathol. 2007;170(5):1435-44. http://dx.doi.org/10.2353/ajpath.2007.060872
de Mendonça A, Vincent JI, Suter PM, Moreno R, Dearden NM, Antonelli M, et al. Acute renal failure in the ICU: risk factors and outcome evaluated by the SOFA score. Intensive Care Med. 2000;26(7):915-21. http://dx.doi.org/10.1007/s001340051281
Brivet FG, Kleinknecht DJ, Loirat P, Landais PJ. Acute renal failure in intensive care units: causes, outcome, and prognostic factors of hospital mortality; a prospective, multicenter study. French Group on Acute Renal Failure. Crit Care Med. 1996;24(2):192-8. http://dx.doi.org/10.1097/00003246-199602000-00003
Ritt LEF, Guimarães, HP, Avezum A, Piegas LS. Statins on sepsis: a new therapeutic gun in intensive care medicine? Rev Bras Ter Intensiva. 2006;18(4):402-406. http://dx.doi.org/10.1590/S0103-507X2006000400014
Williams JM, Greenslade JH, Chu K, Brown AF, Paterson D, Lipman J. Prior statin use is not associated with improved outcome in emergency patients admitted with infection: a prospective observational study. Acad Emerg Med. 2011;18(2):127-34. http://dx.doi.org/10.1111/j.1553-2712.2010.00976.x
Raetz CR. Biochemistry of endotoxins. Annu Rev Biochem. 1990;59:129-170. http://dx.doi.org/10.1146/annurev.bi.59.070190.001021
Flo TH, Halaas O, Torp S, Ryan L, Lien E, Dybdahl B, et al. Differential expression of Toll-like receptor 2 in human cells. J Leukoc Biol. 2001;69(3):474-81.
Dybdahl B, Wahba A, Lien E, Flo TH, Waage A, Qureshi N, et al. Inflammatory response after open heart surgery: release of heart-shock protein 70 and signaling through toll-like receptor-4. Circulation. 2002;105(6):685-690. http://dx.doi.org/10.1161/hc0602.103617
Schor N. Acute renal failure and the sepsis syndrome. Kidney Int. 2002;61(2):764-76. http://dx.doi.org/10.1046/j.1523-1755.2002.00178.x
Boechat AL, Boechat NO. Sepse: diagnóstico e tratamento. Rev Bras Clin Med São Paulo. 2010;8(5):420-7.
Bone RC, Grodzin CJ, Balk RA. Sepsis: a new hypothesis for pathogenesis of the disease process. Chest. 1997;112(1):235-43. http://dx.doi.org/10.1378/chest.112.1.235
Pober JS, Bevilacqua MP, Mendrick DL, Lapierre LA, Fiers W, Gimbrone MA Jr. Two distinct monokines, interleukin 1 and tumor necrosis factor, each independently induce biosynthesis and transient expression of the same antigen on the surface of cultured human vascular endothelial cells. J Immunol. 1986;136(5):1680-7.
Takemoto M, Liao JK. Pleiotropic effects of 3-hidroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arteriocler Thromb Vasc Biol. 2001;21(11):1712-9. http://dx.doi.org/10.1161/hq1101.098486
Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA. 1998;279(20):1643-50. http://dx.doi.org/10.1001/jama.279.20.1643
Schonbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: satins as antiinflamatory agents? Circulation. 2004;109(21 Suppl 1):II18-26.
Issacsohn J, Setaro JF, Nicholas C, Davey JA, Diotalevi LJ, Christianson DS, et al. Effects of lovastatin therapy on plasminogen activator inhibitor-1 antigen levels. Am J Cardiol. 1994;74(7):735-7.
http://dx.doi.org/10.1016/0002-9149(94)90322-0
Sakamoto K, Sakamoto T, Ogawa H. The effect of 6 months of treatment with pravastatin on serum adiponection concentrations in Japanese patients with coronary artery disease and hypercholesterolemia: a pilot study. Clin Ther. 2006;28(7):1012-21. http://dx.doi.org/10.1016/j.clinthera.2006.07.001
Farmer JA. Pleiotropic effects of statins. Curr Atheroscler Rep. 2000;2(3):208-17. http://dx.doi.org/10.1007/s11883-000-0022-3
Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, et al. Measurement of C-reactive protein for the targeting of statins therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344(26):1959-65. http://dx.doi.org/10.1056/NEJM200106283442601
Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, Tiemann M, et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest. 2001;108(3):391-7. http://dx.doi.org/10.1172/JCI200113152
Terada Y, Inoshita S, Nakashima O, Yamada T, Kuwahara M, Sasaki S, et al. Lovastatin inhibits mesangial cell proliferation via p27Kip1. J Am Soc Nephrol. 1998;9(12):2235-43.
Sparrow CP, Burton CA, Hernandez M, Mundt S, Hassing H, Patel S, et al. Simvastatin has anti-inflamatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol. 2001;21(1):115-21. http://dx.doi.org/10.1161/01.ATV.21.1.115
Zoja C, Corna D, Rottoli D, Cattaneo D, Zanchi C, Tomasoni S, et al. Effect of combining ACE inhibitor and statin in severe experimental nephropathy. Kidney Int. 2002;61(5):1635-45. http://dx.doi.org/10.1046/j.1523-1755.2002.00332.x
Novak V, Eisinger M, Frenkel A, Terblanche M, Adhikari NK, Douvdevani A, et al. The effects of statin therapy on inflammatory cytokines in patients with bacterial infections: a randomized double-blind placebo controlled clinical Trial. Intensive Care Med. 2009;35(7):1255-60. http://dx.doi.org/10.1007/s00134-009-1429-0
Kruger PS, Harward ML, Jones MA, Joyce CJ, Kostner KM, Roberts MS, et al. Continuation of statin therapy in patients with presumed infection a randomized controlled trial. Am J Respir Crit Care Med. 2011;183(6):774-81. http://dx.doi.org/10.1164/rccm.201006-0955OC
Nseir W, Mograbi J, Abu-Elheja O, Bishara J, Assy N. The impact of prior long-term versus short-term statin use on the mortality of bacteraemic patients. Infection. 2012;40(1):41-8. http://dx.doi.org/10.1007/s15010-011-0190-9
Patel JM, Snaith C, Thickett DR, Linhartova L, Melody T, Hawkey P, et al. Randomized double-blind placebo-controlled trial of 40 mg/day of atorvastatin in reducing the severity of sepsis in ward patients (ASEPSIS Trial). Crit Care. 2012;16(6):R231. http://dx.doi.org/10.1186/cc11895
Donnino MW, Cocchi MN, Howell M, Clardy P, Talmor D, Cataldo L, et al. Statin therapy is associated with decreased mortality in patients with infection. Acad Emerg Med. 2009;16(3):230-4. http://dx.doi.org/10.1111/j.1553-2712.2009.00350.x
Mekontso Dessap A, Ouanes I, Rana N, Borghi B, Bazin C, Katsahian S, et al. Effects of discontinuing or continuing ongoing statin therapy in severe sepsis and septic shock: a retrospective cohort study. Crit Care. 2011;15(4):R171. http://dx.doi.org/10.1186/cc10317
Williams JM, Greenslade JH, Chu K, Brown AF, Paterson D, Lipman J. Prior statin use is not associated with improved outcome in emergency patients admitted with infection: a prospective observational study. Acad Emerg Med. 2011;18(2):127-34. http://dx.doi.org/10.1111/j.1553-2712.2010.00976.x
. Leung S, Pokharel R, Gong MN. Statins and outcomes in patients with bloodstream infection: a propensity-matched analysis. Crit Care Med. 2012;40(4):1064-71.http://dx.doi.org/10.1097/CCM.0b013e31823bc9e7
. Knopp RH. Drug treatment of lipid disorders. N Engl J Med. 1999;341(7):498-511.
Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:(9493):1267-78.
Tolman KG. The liver and lovastatin. Am J Cardiol. 2002;89(12):1374-80. http://dx.doi.org/10.1016/S0002-9149(02)02355-X
Carrillo-Esper R, Rivera-Buendía S, Carrillo-Córdova JR, Carrillo-Córdova LD. Estatinas, ¿alternativa terapéutica en sepsis? Gac Méd Méx. 2007;143(6):499-3.